over a month ago at Macroaxis 
By Ellen Johnson
In this article I will examine Trustmark. I will concentrate on why it could be a much better year for Trustmark traders. Is the stock valuation justified? Here I will also cover Trustmark prospective on valuation to give you a better outlook on taking a position in this stock. What is Trustmark Target Price Odds to finish over Current Price? Coming from normal probability distribution, the odds of Trustmark to move above current price in 30 days from now is about 11.4%. The Trustmark Corporation probability density function shows the probability of Trustmark Stock to fall within a particular range of prices over 30 days . Given the investment horizon of 30 days, Trustmark has beta of 0.7335 . This entails as returns on market go up, Trustmark average returns are expected to increase less than the benchmark. However during bear market, the loss on holding Trustmark Corporation will be expected to be much smaller as well. Additionally, the company has a negative alpha implying that the risk taken by holding this equity is not justified. Trustmark is significantly underperforming Russell 2000 .
 Trustmark  valuation ideas   trustmark financial services banks?regional
  over a month ago at Macroaxis 
By Achuva Shats
Is TCW Enhanced Commmodity valuation justified? Here I will cover the entity prospective on valuation to give you a better outlook on taking a position in this fund. We consider TCW Enhanced slightly risky. TCW Enhanced Commmodity owns Efficiency Ratio (i.e. Sharpe Ratio) of 0.008 which indicates the fund had 0.008% of return per unit of risk over the last 1 month. Our way in which we are measuring volatility of a fund is to use all available market data together with fund specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for TCW Enhanced Commmodity Strateg which you can use to evaluate future volatility of the entity. Please validate TCW Enhanced Market Risk Adjusted Performance of (0.19) to confirm if risk estimate we provide are consistent with the epected return of 0.0065%.
 TCW Enhanced  valuation ideas   tcw enhanced tcw commodities broad basket
  over a month ago at Macroaxis 
By Achuva Shats
Is Direxion Daily Russia valuation justified? Here I will cover the entity prospective on valuation to give you a better outlook on taking a position in this direxion daily russia bull 3x shares. Macroaxis considers Direxion Daily to be not too volatile. Direxion Daily Russia secures Sharpe Ratio (or Efficiency) of -0.0117 which denotes the direxion daily russia bull 3x shares had -0.0117% of return per unit of risk over the last 1 month. Macroaxis philosophy towards predicting risk of any direxion daily russia bull 3x shares is to look at both systematic and un-systematic factors of the business, including all available market data and technical indicators. Direxion Daily Russia Bull 3x S exposes twenty-one different technical indicators which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Direxion Daily Russia Coefficient Of Variation of (5,246) and Mean Deviation of 2.19 to check risk estimate we provide.
 Direxion Daily  valuation ideas   direxion daily direxion funds trading--leveraged equity
  over a month ago at Macroaxis 
By Vlad Skutelnik
Is the organisation valuation justified? Here I will cover the company prospective on valuation to give you a better outlook on taking a position in this stock. We found thirty-eight available fundamental indicators for Bristol Myers Squibb Company which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Bristol Myers Squibb fundamentals including its Price to Earning, Book Value Per Share, Current Liabilities, as well as the relationship between Net Income and Beta . Given that Bristol Myers Squibb has Price to Earning of 13.19 , we suggest you validate Bristol Myers Squibb Company prevailing market performance to make sure the company can sustain itself down the road. Use Bristol Myers to enhance returns of your portfolios. The stock experiences moderate upward volatility. Check odds of Bristol Myers to be traded at $60.25 in 30 days.
 Bristol Myers  valuation ideas   bristol myers healthcare drug manufacturers - general pharmaceutical products drug manufacturers?general
  over a month ago at Macroaxis 
By Ellen Johnson
Is the stock valuation justified? Here I will cover Brookline Bancorp prospective on valuation to give you a better outlook on taking a position in this stock. What is Brookline Bancorp Target Price Odds to finish over Current Price? Out from normal probability distribution, the odds of Brookline Bancorp to move above current price in 30 days from now is near 1%. The Brookline Bancorp probability density function shows the probability of Brookline Bancorp Stock to fall within a particular range of prices over 30 days . Given the investment horizon of 30 days, Brookline Bancorp has beta of 0.6621 . This suggests as returns on market go up, Brookline Bancorp average returns are expected to increase less than the benchmark. However during bear market, the loss on holding Brookline Bancorp will be expected to be much smaller as well. Additionally, the company has an alpha of 0.0775 implying that it can potentially generate 0.0775% excess return over Russell 2000 after adjusting for the inherited market risk (beta).
 Brookline Bancorp  valuation ideas   brookline bancorp financial services banks - regional banking banks?regional
  over a month ago at Macroaxis 
By Ellen Johnson
Is the stock valuation justified? Here I will cover Washington Federal prospective on valuation to give you a better outlook on taking a position in this stock. What is Washington Federal Target Price Odds to finish over Current Price? Pertaining to normal probability distribution, the odds of Washington Federal to move above current price in 30 days from now is about 27.91%. The Washington Federal probability density function shows the probability of Washington Federal Stock to fall within a particular range of prices over 30 days . Given the investment horizon of 30 days, Washington Federal has beta of 0.7627 . This means as returns on market go up, Washington Federal average returns are expected to increase less than the benchmark. However during bear market, the loss on holding Washington Federal will be expected to be much smaller as well. Additionally, the company has an alpha of 0.0743 implying that it can potentially generate 0.0743% excess return over Russell 2000 after adjusting for the inherited market risk (beta).
 Washington Federal  valuation ideas   washington federal financial services banks?regional
  over a month ago at Macroaxis 
By Vlad Skutelnik
This post is geared to all Advanced Drainage management as well as to investors considering exiting their position in the enterprise. I will evaluate if Advanced Drainage shares are sensibly priced going into November and whether management should be worried. Is the stock valuation justified? Here I will also cover Advanced Drainage prospective on valuation to give you a better outlook on taking a position in this stock. We found thirty-seven available fundamental indicators for Advanced Drainage Systems which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Advanced Drainage fundamentals including its Cash Flow from Operations, and the relationship between Cash and Equivalents and Market Capitalization . Given that Advanced Drainage has Price to Earning of 26.98 , we suggest you validate Advanced Drainage Systems prevailing market performance to make sure the company can sustain itself down the road. Use Advanced Drainage to protect your portfolios against small markets fluctuations. The stock experiences normal downward trend and little activity. Check odds of Advanced Drainage to be traded at $35.8 in 30 days.
 Advanced Drainage  valuation ideas   advanced drainage industrials building products & equipment
  over two months ago at Macroaxis 
By Vlad Skutelnik
Is Amdocs valuation justified? Here I will cover the organisation prospective on valuation to give you a better outlook on taking a position in this stock. Amdocs Limited shows prevailing Real Value of $74.49 per share. The current price of the firm is $65.92. At this time the firm appears to be undervalued. This module approximates value of Amdocs Limited from analyzing the firm fundamentals such as Return On Equity of 0.0011 and Profit Margin of 0.001 as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.
 Amdocs  valuation ideas   amdocs technology software - infrastructure business services software?infrastructure
  over two months ago at Macroaxis 
By Vlad Skutelnik
This article is aimed at all current or potential Citigroup investors. I will look into why albeit cyclical market disturbance, the long term basic indicators of the company are still strong. Is the organisation valuation justified? Here I will also cover the company prospective on valuation to give you a better outlook on taking a position in this stock. Citigroup shows prevailing Real Value of $76.91 per share. The current price of the firm is $69.55. At this time the firm appears to be undervalued. This module approximates value of Citigroup from analyzing the firm fundamentals such as Profit Margin of 28.35%, Return On Equity of 9.26% and Shares Outstanding of 2.26B as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.
 Citigroup  valuation ideas   citigroup financial services banks - diversified banking banks?diversified
  over two months ago at Macroaxis 
By Vlad Skutelnik
In this write-up I will digest Erie Indemnity. I will look into why despite ongoing dip, the longer-term fundamental drivers of the firm are still sound. Is the organisation valuation justified? Here I will also cover the company prospective on valuation to give you a better outlook on taking a position in this stock. Erie Indemnity shows prevailing Real Value of $209.59 per share. The current price of the firm is $190.03. At this time the firm appears to be undervalued. This module computes value of Erie Indemnity from reviewing the firm fundamentals such as Current Valuation of 10.47B, Shares Outstanding of 46.19M and Profit Margin of 12.58% as well as analyzing its technical indicators and Probability Of Bankruptcy. In general, we advise to go long with undervalued instruments and to sell out overvalued instruments since at some point assets prices and their ongoing real values will submerge.
 Erie Indemnity  valuation ideas   erie indemnity financial services insurance brokers insurance

Share Stories

Syndicate Stories to major social sites

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Thematic Ideas
Explore Investing Ideas  
Search macroaxis.com